hypoproliferative

Current guidelines recommend a threshold of 10 × 10 9 /L for prophylactic platelet transfusion and as suitable in patients without additional risk factors (eg, sepsis, concurrent use of antibiotics, and other abnormalities of hemostasis). 21, 22 In a trial investigating the efficacy and safety of therapeutic versus prophylactic platelet transfusion to prevent bleeding in patients with hypoproliferative thrombocytopenia, the authors recommended that in patients with acute myeloid leukemia prophylactic platelet administration should remain the standard of care. 23 A similar threshold of 10 × 10 9 /L was recommended by the American Society of Clinical Oncology in their clinical practice guidelines for platelet transfusion in patients with cancer. 1 This recommendation was made for adult patients receiving therapy for acute leukemia, and patients with solid tumors during chemotherapy-induced thrombocytopenia.

2015, Bernhard Ziegler et al., “Thromboelastometric Monitoring of the Hemostatic Effect of Platelet Concentrates Transfusion in Thrombocytopenic Children Undergoing Chemotherapy”, in Clinical and Applied Thrombosis/Hemostasis, volume 21, →DOI